期刊
TRENDS IN MOLECULAR MEDICINE
卷 19, 期 11, 页码 685-694出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2013.08.007
关键词
TRAIL; apoptesis; cancer; targeted therapy; stem cells
资金
- James S. McDonnell Foundation
- [R01CA138922]
- [R01CA173077]
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand, or TRAIL, is a promising anticancer agent as it can induce apoptosis in a wide range of cancers whilst generally sparing non-malignant cells. However, the translation of TRAIL into the clinic has been confounded by its short half-life, inadequate delivery methods, and TRAIL-resistant cancer cell populations. In this review, we discuss how TRAIL has been functionalized to diversify its traditional tumor-killing role and novel strategies to facilitate its effective deployment in preclinical cancer models. The successes and failures of the most recent clinical trials using TRAIL agonists are highlighted and we provide a perspective for improving its clinical implementation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据